Immunis is a private biotechnology company pursuing novel stem cell-derived treatments for age and disease-related immune decline. Our STEM product leverages our leading-edge capabilities in stem cell culture to deliver a product of all natural, all human immune modulators in their natural relative concentrations. Immunis is currently testing STEM in a Phase 1/2a clinical trial for muscle atrophy.